All Stories

  1. Reactions of Medicinal Gold Compounds with Cathepsin B Explored through Electrospray Mass Spectrometry Measurements
  2. Exploring pta Alternatives in the Development of Ruthenium–Arene Anticancer Compounds
  3. Novel Organoruthenium(II) Complex C1 Selectively Inhibits Butyrylcholinesterase without Side Effects on Neuromuscular Transmission
  4. Copper(ii) and silver(i) complexes with dimethyl 6-(pyrazine-2-yl)pyridine-3,4-dicarboxylate (py-2pz): the influence of the metal ion on the antimicrobial potential of the complex
  5. Silver(I) Complexes with Clinically Used Azoles: Synthesis, Structural Characterization and Antimicrobial Evaluation
  6. Coordination preferences of NNO and NNS Schiff base ligands with Co(III) complexes: Synthesis, characterization and DFT calculation
  7. Nanosecond electric pulses are equally effective in electrochemotherapy with cisplatin as microsecond pulses
  8. Kinetic Characterization of Cerium and Gallium Ions as Inhibitors of Cysteine Cathepsins L, K, and S
  9. Ruthenium complexes show potent inhibition of AKR1C1, AKR1C2, and AKR1C3 enzymes and anti-proliferative action against chemoresistant ovarian cancer cell line
  10. Zinc pyrithione is a potent inhibitor of PLPro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication
  11. Zinc(II) Complexes with Dimethyl 2,2′-Bipyridine-4,5-dicarboxylate: Structure, Antimicrobial Activity and DNA/BSA Binding Study
  12. Metal(II) Complexes of the Fluoroquinolone Fleroxacin: Synthesis, Characterization and Biological Profile
  13. Zinc pyrithione is a potent inhibitor of PLPro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication
  14. Clinically used antifungal azoles as ligands for gold(iii) complexes: the influence of the Au(iii) ion on the antimicrobial activity of the complex
  15. Cu(ii), Mn(ii) and Zn(ii) complexes of hydrazones with a quaternary ammonium moiety: synthesis, experimental and theoretical characterization and cytotoxic activity
  16. Pyrithione metal (Cu, Ni, Ru) complexes as photo-catalysts for styrene oxide production
  17. Fine Tuning of Cholinesterase and Glutathione-S-Transferase Activities by Organoruthenium(II) Complexes
  18. Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance
  19. Comparison of Solution Chemical Properties and Biological Activity of Ruthenium Complexes of Selected β-Diketone, 8-Hydroxyquinoline and Pyrithione Ligands
  20. Organoruthenium Complexes with Benzo-Fused Pyrithiones Overcome Platinum Resistance in Ovarian Cancer Cells
  21. Large enhancement of photocatalytic activity in ZnO thin films grown by plasma-enhanced atomic layer deposition
  22. Structural Characterization, Antimicrobial Activity and BSA/DNA Binding Affinity of New Silver(I) Complexes with Thianthrene and 1,8-Naphthyridine
  23. Structure of Biologically Active Benzoxazoles: Crystallography and DFT Studies
  24. Tailoring copper(ii) complexes with pyridine-4,5-dicarboxylate esters for anti-Candida activity
  25. Copper(II) and Zinc(II) Complexes with the Clinically Used Fluconazole: Comparison of Antifungal Activity and Therapeutic Potential
  26. Synthesis, X-ray structures and magnetic properties of Ni(II) complexes of heteroaromatic hydrazone
  27. Synthesis, structural determination, in vitro and in silico biological evaluation of divalent or trivalent cobalt complexes with indomethacin
  28. Synthesis, Characterization, Catalytic Activity, and DFT Calculations of Zn(II) Hydrazone Complexes
  29. Cobalt(II), Zinc(II), Iron(III), and Copper(II) Complexes Bearing Positively Charged Quaternary Ammonium Functionalities: Synthesis, Characterization, Electrochemical Behavior, and SOD Activity
  30. Structural Isomerism and Enhanced Lipophilicity of Pyrithione Ligands of Organoruthenium(II) Complexes Increase Inhibition on AChE and BuChE
  31. Structural and functional characterization of an organometallic ruthenium complex as a potential myorelaxant drug
  32. Binding Kinetics of Ruthenium Pyrithione Chemotherapeutic Candidates to Human Serum Proteins Studied by HPLC-ICP-MS
  33. Silver(i) complexes with different pyridine-4,5-dicarboxylate ligands as efficient agents for the control of cow mastitis associated pathogens
  34. Synthesis, X-ray structure and DFT calculation of magnetic properties of binuclear Ni(II) complex with tridentate hydrazone-based ligand
  35. Combined Experimental and Theoretical Investigation of the Origin of Magnetic Anisotropy in Pentagonal Bipyramidal Isothiocyanato Co(II), Ni(II) and Fe(III) Complexes With Quaternary Ammonium-functionalized 2,6-Diacetylpyridine Bisacylhydrazone
  36. Towards Identification of Essential Structural Elements of Organoruthenium(II)‐Pyrithionato Complexes for Anticancer Activity
  37. Covalent versus Noncovalent Binding of Ruthenium η 6 ‐ p ‐Cymene Complexes to Zinc‐Finger Protein NCp7
  38. Organoruthenated Nitroxoline Derivatives Impair Tumor Cell Invasion through Inhibition of Cathepsin B Activity
  39. What Is the Nature of Interactions of BF4–, NO3–, and ClO4– to Cu(II) Complexes with Girard’s T Hydrazine? When Can Binuclear Complexes Be Formed?
  40. Highly-efficient N-arylation of imidazole catalyzed by Cu(II) complexes with quaternary ammonium-functionalized 2-acetylpyridine acylhydrazone
  41. Organometallic ruthenium(II)-arene complexes with triphenylphosphine amino acid bioconjugates: Synthesis, characterization and biological properties
  42. Organoruthenium(II) complexes of acetazolamide potently inhibit human carbonic anhydrase isoforms I, II, IX and XII
  43. Anti-cancer organoruthenium(ii) complexes and their interactions with cysteine and its analogues. A mass-spectrometric study
  44. Comparative antitumor studies of organoruthenium complexes with 8-hydroxyquinolines on 2D and 3D cell models of bone, lung and breast cancer
  45. Synthesis, Biological Evaluation and Docking Studies of Benzoxazoles Derived from Thymoquinone
  46. Synthesis, structures and magnetic properties of octahedral Co(III) complexes of heteroaromatic hydrazones with tetraisothiocyanato Co(II) anions
  47. Organoruthenium Prodrugs as a New Class of Cholinesterase and Glutathione-S-Transferase Inhibitors
  48. Synthesis and biological characterization of organoruthenium complexes with 8-hydroxyquinolines
  49. C-H Bond Activation by a Ruthenium(II) β -Diketonate Complex: A Mechanistic Study
  50. Structural diversity of isothiocyanato Cd(II) and Zn(II) Girard’s T hydrazone complexes in solution and solid state: effect of H-bonding on coordination number and supramolecular assembly of Cd(II) complex in solid state
  51. Crystal structures and DFT calculations of mixed chloride-azide zinc(II) and chloride-isocyanate cadmium(II) complexes with the condensation product of 2-quinolinecarboxaldehyde and Girard's T reagent
  52. Concomitant polymorphism in an organometallic ruthenium(II) complex with an N,N′-donor ligand
  53. Manganese(II) complexes of the quinolone family member flumequine: Structure, antimicrobial activity and affinity for albumins and calf-thymus DNA
  54. Correction to: Exploration of selected electronic characteristics of half-sandwich organoruthenium(II) β-diketonate complexes
  55. Exploration of selected electronic characteristics of half-sandwich organoruthenium(II) β-diketonate complexes
  56. Molecular Structures and Spin-States of Pseudohalide Metal Complexes with Hydrazones of Girard's T Reagent
  57. A new class of platinum(ii) complexes with the phosphine ligand pta which show potent anticancer activity
  58. How zinc ions shift and enhance the nucleotide's fluorescence spectra
  59. Extending the family of quinolone antibacterials to new copper derivatives: self-assembly, structural and topological features, catalytic and biological activity
  60. Crystal structures, magnetic properties and DFT study of cobalt(II) azido complexes with the condensation product of 2-quinolinecarboxaldehyde and Girard’s T reagent
  61. Synthesis, characterization and antimicrobial activity of isothiocyanato Fe(III) Girard's t hydrazone complex
  62. Synthesis, characterization, DFT calculations and antimicrobial activity of Cd(II) complexes with the condensation product of 2-quinolinecarboxaldehyde and Girard’s T reagent
  63. Synthesis, crystal structures and antimicrobial activity of azido and isocyanato Zn(II) complexes with the condensation product of 2-quinolinecarboxaldehyde and Girard’s T reagent
  64. Synthesis, characterization and crystal structures of two pentagonal-bipyramidal Fe(III) complexes with dihydrazone of 2,6-diacetylpyridine and Girard's T reagent. Anticancer properties of various metal complexes of the same ligand
  65. Synthesis, crystal structure, magnetic properties and DFT study of dinuclear Ni(II) complex with the condensation product of 2-quinolinecarboxaldehyde and Girard’s T reagent
  66. Synthesis and Structural Evaluation of Organo-Ruthenium Complexes with β-Diketonates
  67. β-Diketones as Scaffolds for Anticancer Drug Design - From Organic Building Blocks to Natural Products and Metallodrug Components
  68. Copper(II) complexes with gatifloxacin
  69. Cobalt(II) complexes of sparfloxacin
  70. Synthesis, characterization, DFT calculations and antimicrobial activity of pentagonal-bipyramidal Zn(II) and Cd(II) complexes with 2,6-diacetylpyridine-bis(trimethylammoniumacetohydrazone)
  71. Co-NSAIDs
  72. Interactions of two cytotoxic organoruthenium(II) complexes with G-quadruplex
  73. Interactions of the “piano-stool” [ruthenium(II)(η6-arene)(quinolone)Cl]+complexes with water; DFT computational study
  74. Synthesis, characterization and antimicrobial activity of pentagonal-bipyramidal isothiocyanato Co(II) and Ni(II) complexes with 2,6-diacetylpyridine bis(trimethylammoniumacetohydrazone)
  75. Synthesis and characterization of ML and ML2 metal complexes with amino acid substituted bis(2-picolyl)amine ligands
  76. Pyrithione-based ruthenium complexes as inhibitors of aldo–keto reductase 1C enzymes and anticancer agents
  77. Structure and biological activities of metal complexes of flumequine
  78. Clioquinol–ruthenium complex impairs tumour cell invasion by inhibiting cathepsin B activity
  79. Investigation of antitumor potential of Ni(II) complexes with tridentate PNO acylhydrazones of 2-(diphenylphosphino)benzaldehyde and monodentate pseudohalides
  80. Ruthenium complexes as inhibitors of 15-lipoxygenase-1
  81. Synthesis, crystal structures, and antimicrobial activity of square-planar chloride and isocyanate Ni(II) complexes with the condensation product of 2-(diphenylphosphino)benzaldehyde and Girard’s T reagent
  82. New synthetic routes for the preparation of ruthenium-1,10-phenanthroline complexes. Tests of cytotoxic and antibacterial activity of selected ruthenium complexes
  83. Ruthenium complexes as inhibitors of the aldo–keto reductases AKR1C1–1C3
  84. Structure-Related Mode-of-Action Differences of Anticancer Organoruthenium Complexes with β-Diketonates
  85. Special Issue: Practical Applications of Metal Complexes
  86. Experimental and theoretical investigation of octahedral and square-planar isothiocyanato complexes of Ni(II) with acylhydrazones of 2-(diphenylphosphino)benzaldehyde
  87. Manganese(II)–sparfloxacinato complexes
  88. Cobalt-oxolinato complexes
  89. New method for the speciation of ruthenium-based chemotherapeutics in human serum by conjoint liquid chromatography on affinity and anion-exchange monolithic disks
  90. Synthesis, characterization, DFT calculation and biological activity of square-planar Ni(II) complexes with tridentate PNO ligands and monodentate pseudohalides. Part II
  91. Cobalt(II) complexes of enrofloxacin
  92. Modulation of Activity of Known Cytotoxic Ruthenium(III) Compound (KP418) with Hampered Transmembrane Transport in Electrochemotherapy In Vitro and In Vivo
  93. New Water-Soluble Ruthenium(II) Terpyridine Complexes for Anticancer Activity: Synthesis, Characterization, Activation Kinetics, and Interaction with Guanine Derivatives
  94. Synthesis and Biological Evaluation of Organoruthenium Complexes with Azole Antifungal Agents. First Crystal Structure of a Tioconazole Metal Complex
  95. Zinc-tolfenamato
  96. Analysis of the structures of the Cu(I) and Cu(II) complexes with 3-acetylpyridine and thiocyanate
  97. Manganese(II) complexes of tolfenamic acid
  98. Structural characterization and biological evaluation of a clioquinol–ruthenium complex with copper-independent antileukaemic activity
  99. Zinc complexes of mefenamic acid
  100. Synthesis, characterization, DFT calculations and biological activity of derivatives of 3-acetylpyridine and the zinc(II) complex with the condensation product of 3-acetylpyridine and semicarbazide
  101. New Uses for Old Drugs: Attempts to Convert Quinolone Antibacterials into Potential Anticancer Agents Containing Ruthenium
  102. Manganese(II) complexes of niflumic acid
  103. Zinc complexes of oxolinic acid, flumequine, enrofloxacin
  104. Novel Organoruthenium(II) β-Diketonates as Catalysts for Ortho Arylation via C–H Activation
  105. Zinc complexes of flumequine
  106. Copper complexes with ofloxacin and norfloxacin - synthesis, structure na bioactivity
  107. Copper(II) complexes of flumequine
  108. Synthesis and Biological Evaluation of the Thionated Antibacterial Agent Nalidixic Acid and Its Organoruthenium(II) Complex
  109. Cobalt(II)-tolfenamato complexes
  110. Factors that influence the antiproliferative activity of half sandwich RuII–[9]aneS3 coordination compounds: activation kinetics and interaction with guanine derivatives
  111. Copper - diflunisal
  112. Interactions of Metal Ions with DNA, Its Constituents and Derivatives, which may be Relevant for Anticancer Research
  113. Nickel–quinolones-bipyam complexes
  114. Synthesis, characterization, cytotoxic activity and DNA binding properties of the novel dinuclear cobalt(III) complex with the condensation product of 2-acetylpyridine and malonic acid dihydrazide
  115. Physicochemical Studies and Anticancer Potency of Ruthenium η6-p-Cymene Complexes Containing Antibacterial Quinolones
  116. Copper(II) complexes of naproxen / diclofenac
  117. 1-(2-Picolyl)-substituted 1,2,3-triazole as novel chelating ligand for the preparation of ruthenium complexes with potential anticancer activity
  118. Zinc complexes of sparfoxacin - levofloxacin
  119. First Ruthenium Organometallic Complex of Antibacterial Agent Ofloxacin. Crystal Structure and Interactions with DNA
  120. Pyridyl Conjugated 1,2,3-Triazole is a Versatile Coordination Ability Ligand Enabling Supramolecular Associations
  121. Di-μ-chlorido-bis{chlorido[(R)/(S)-1,5-diphenyl-3-(2-pyridyl-κN)-2-pyrazoline-κN2]zinc(II)}
  122. Nickel complexes of flumequine
  123. Intermolecular C—H...π interactions in 1,5-diphenyl-3-(2-pyridyl)-2-pyrazoline
  124. Click-Triazole N2 Coordination to Transition-Metal Ions Is Assisted by a Pendant Pyridine Substituent
  125. Strong Correlations in Highly Electron-Doped Zn(II)-DNA Complexes
  126. Nickel complexes of oxolinic acid
  127. Synthesis and Characterization of Novel Ruthenium(III) Complexes with Histamine
  128. Magnesium complexes of ciprofloxacin
  129. Spectral properties of Eu(III) compound with antibacterial agent ciprofloxacin (cfqH). Crystal structure of [Eu(cfqH)(cfq)(H2O)4]Cl2·4.55H2O
  130. Combined therapy of the antimetastatic compound NAMI-A and electroporation on B16F1 tumour cells in vitro
  131. Erratum to: Synthesis, characterization and DNA binding of magnesium-ciprofloxacin (cfH) complex [Mg(cf)2] · 2.5H2O [J. Inorg. Biochem. 100 (2006) 1705–1713]
  132. Optical spectra of wet and dry M -DNA
  133. Experimental electron density study of a complex between copper(ii) and the antibacterial quinolone family member ciprofloxacin
  134. X-Ray crystallographic, NMR and antimicrobial activity studies of magnesium complexes of fluoroquinolones – racemic ofloxacin and its S-form, levofloxacin
  135. catena-Poly[[[tetrakis(μ-acetato-κ2O:O′)dirhodium(II)]-μ-[1,3-bis(dimethylamino)propan-2-ol-κ2N:N′]] tetrahydrofuran hemisolvate]
  136. Synthesis, characterization and DNA binding of magnesium–ciprofloxacin (cfH) complex [Mg(cf)2]·2.5H2O
  137. Ruthenium complexes with purine derivatives: Syntheses, structural characterization and preliminary studies with plasmidic DNA
  138. Mixed-valence Cu(II)/Cu(I) complex of quinolone ciprofloxacin isolated by a hydrothermal reaction in the presence of l-histidine: comparison of biological activities of various copper–ciprofloxacin compounds
  139. Solution, solid state and biological characterization of ruthenium(III)-DMSO complexes with purine base derivatives
  140. A novel copper(II) complex with 1,10-phenanthroline and ciprofloxacin
  141. Influence of copper(II) and magnesium(II) ions on the ciprofloxacin binding to DNA
  142. Ruthenium(III)-DMSO complexes of the antiherpes drug acyclovir
  143. Characterization of ciprofloxacin binding to the linear single- and double-stranded DNA
  144. Interactions of oxovanadium(IV) and the quinolone family member—ciprofloxacin
  145. Crystal Structure of Ciprofloxacin Hydrochloride 1.34-Hydrate.
  146. Interaction between ciprofloxacin and DNA mediated by Mg2+-ions
  147. The interactions of metal ions with quinolone antibacterial agents
  148. Novel RuIII-DMSO Complexes of the Antiherpes Drug Acyclovir
  149. Erratum to In vitro study of the insulin-mimetic behaviour of vanadium(IV, V) coordination compounds
  150. In vitro study of the insulin-mimetic behaviour of vanadium(IV, V) coordination compounds
  151. Biological Activity of Some Magnesium(II) Complexes of Quinolones
  152. NMR Investigation of the Copper(II)-Ciprofloxacin System
  153. Complexes of copper (II) acetate with nicotinamide: preparation, characterization and fungicidal activity; crystal structures of [Cu2 (O2CCH3)4 (nia)] and [Cu2 (O2CCH3)4 (nia)2]
  154. New studies in the copper(II) acyclovir (acv) system. NMR relaxation studies and the X-ray crystal structure of [Cu(acv)2(H2O)2](NO3)2
  155. Antibacterial tests of Bismuth(III)–Quinolone (Ciprofloxacin, cf) compounds against Helicobacter pylori and some other bacteria. Crystal structure of (cfH2)2[Bi2Cl10]·4H2O
  156. Complexes of copper(II) carboxylates with 2-aminoethanol - syntheses, characterization and fungicidal activity; crystal structure of Cu(O2CC8H17)2(NH2C2H4OH)2
  157. Effect of Copper Acyclovir Complexes on Herpes Simplex Virus Type 1 and Type 2 (HSV-1, HSV-2) Infection in Cultured Cells
  158. Boron Complex of a Member of the Quinolone Family
  159. Crystal structure of ciprofloxacin hexahydrate and its characterization
  160. Crystal structure and characterization of the bismuth(III) compound with quinolone family member (ciprofloxacin). Antibacterial study
  161. Synthesis, crystal structure, and characterization of two metal-quinolone compounds
  162. Synthesis and characterization of copper(II) coordination compounds with acyclovir: crystal structure of triaquabis [9-{(2-hydroxyethoxy)methyl>guanine] copper(II) nitrate (V) hydrate
  163. An Adduct of Magnesium Sulfate with a Member of the Quinolone Family (Ciprofloxacin)
  164. Comparison of the thermal stability of ciprofloxacin and its compounds
  165. The crystal structure and characterization of a copper(II) complex with a guanosine-5′-monophosphate analog (acyclovir monophosphate)
  166. Synthesis, crystal structure, and characterization of three novel compounds of the quinolone family member (norfloxacin)
  167. Complex formation between some metals and a quinolone family member (ciprofloxacin)
  168. Synthesis, characterization, and crystal structure of a copper(II) complex with quinolone family member (ciprofloxacin): bis(1)-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazin-1ylquinoline-3-carboxylate) copper(II) chloride hexahydrate
  169. Synthesis and structure of diaquadichlorobis {9-[(2-hydroxyethoxy)methyl]guanine} copper(II)